Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the medication adherence, clinical efficacy, and safety of
EnvarsusXR in stable post liver transplant patient using a Phase III randomized controlled
study. The primary outcome is change in medication adherence from baseline to the end of the
study, assessed using a validated instrument (BAASIS- Basel Assessment of Adherence with
Immunosuppressive medication Scales) and standard deviation of Tacrolimus levels.